Back

Comparison of stroke and major bleeding risk of treatment with apixaban vs. rivaroxaban and dabigatran among elderly nonvalvular atrial fibrillation patients in the United States

29 August 2017 (15:12 - 15:21)
Organised by:
Congress Presentation Part of: Anticoagulation in atrial fibrillation Atrial fibrillation (AF) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Steven Deitelzweig

Ochsner Medical Center, New Orleans (United States of America)

9 More presentations in this session

Presentation thumbnail
Atrial fibrillation and venous thromboembolism. a Swedish nationwide registry study on 1358274 individuals.
Assistant Professor B. Hornestam (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Higher risk of dementia without oral anticoagulation in atrial fibrillation
Associate Professor L. Friberg (Bromma, SE)
Abstract Slides Video
Presentation thumbnail
Anticoagulant use and associated outcomes in patients with atrial fibrillation and advanced kidney disease
Doctor P. Noseworthy (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Age and gender differences in stroke and bleeding risks in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants
Doctor P. Noseworthy (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Similar long-term risk of thromboembolic events in postoperative atrial fibrillation following coronary artery bypass grafting and non-valvular atrial fibrillation: need for anticoagulation?
Mr J. Butt (Copenhagen, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Anticoagulation in atrial fibrillation

The Event

Event poster

ESC Congress 2017

29 August 2017 15:12 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources